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Abstract
Hsp90 chaperones contain an N-terminal ATP binding site that has been effectively targeted by
competitive inhibitors. Despite the myriad of inhibitors, none to date have been designed to bind
specifically to just one of the four mammalian hsp90 paralogs, which are cytoplasmic Hsp90α and
β, ER GRP94, and mitochondrial Trap-1. Given that each of the hsp90 paralogs is responsible for
chaperoning a distinct set of client proteins, specific targeting of one hsp90 paralog may result in
higher efficacy and therapeutic control. Specific inhibitors may also help elucidate the biochemical
roles of each hsp90 paralog. Here we present side by side comparisons of the structures of yeast
Hsp90 and mammalian GRP94, bound to the pan-hsp90 inhibitors Geldanamycin and Radamide.
These structures reveal paralog specific differences in the Hsp90 and GRP94 conformations in
response to Geldanamycin binding. We also report significant variation in the pose and disparate
binding affinities for the Geldanamycin-Radicicol chimera Radamide when bound to the two
paralogs, which may be exploited in the design of paralog-specific inhibitors.
Introduction
Cytosolic Hsp90 and endoplasmic reticulum (ER) resident GRP94 are essential molecular
chaperones1; 2 that belong to the GHKL protein superfamily, which is characterized by the
Bergerat ATP binding fold3; 4. Among the client proteins that require Hsp90 for proper
function are cell-cycle proteins such as Cdc2, Cdk4, Cdk6, and Cdk9, signaling kinases such
as HRI, Raf-1, mutant p53, Akt, ErbB2, and Her2, and steroid hormone receptors5; 6; 7. The
clients of GRP94, which include all Toll-like receptors, certain integrins8, and IgGs9; 10 are
cell surface or secreted proteins that are necessary for monitoring the extracellular milieu,
mediating cell to cell communication, and effecting an immune response.
Competitive inhibition of the Hsp90 ATP binding site leads to the targeted degradation of client
proteins via the ubiquitin proteasome pathway11; 12. Inhibition of Hsp90 results in growth
arrest for tumor cells in culture, and tumor growth inhibition or regression in animal
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models6; 13; 14; 15. While inhibition of Hsp90 leads to degradation of Hsp90 clients, the best
understood response to inhibition of GRP94 is the transcriptional up-regulation of ER
chaperones16.
The anti-cancer effects of Hsp90 inhibition have driven the development of potent antagonists.
Among the first inhibitors to be identified were the natural product ansamycin antibiotics
Geldanamycin (Gdm) and Radicicol (Rdc) (Figure 1)17; 18. The scaffolds of these ansamycins
and the natural ligand ATP have been successfully exploited for inhibitor design13; 19; 20;
21; 22; 23; 24; 25; 26; 27; 28; 29. Gdm has also been used as a tool to better understand the
quaternary structure and regulatory roles of GRP9411; 12.
Despite Gdm’s central place in the arsenal of hsp90 inhibitors, no structural studies have yet
been reported for GRP94 in complex with Gdm. To better understand the binding mode of
Gdm to GRP94 and to guide the use of Gdm as a probe of GRP94 function, we have determined
the structure of the N-terminal regulatory domain of GRP94 bound to Gdm. This structure
reveals that GRP94, unlike Hsp90, must undergo a conformational re-arrangement to
accommodate Gdm in the ATP binding pocket. Moreover, the limited extent of this
rearrangement, compared to that elicited by ATP binding, provides a mechanistic basis for
understanding the other known ligand-dependent conformational changes in GRP94.
Finally, to further address differences in how pan-hsp90 inhibitors interact with the GRP94
and Hsp90 ATP binding site we solved the co-crystal structures of the radicicol-geldanamycin
chimera Radamide23; 26 (Figure 1), bound both to yeast Hsp82 and GRP94. The Radamide
co-crystal structures reveal distinct ligand poses that exploit differences in the ATP binding
sites of Hsp90 and GRP94. Direct binding assays with Radamide revealed disparate affinities
for the two hsp90 paralogs. Taken together, these results demonstrate that GRP94 and Hsp90,
though very similar, interact with a selection of inhibitors in different manners. The observed
differences in protein conformation, ligand pose, and binding affinity present a structure-
function basis for selective inhibition of these important molecular chaperones.
Results
Binding of Geldanamycin requires rotation of Gly198 in GRP94
When Gdm is modeled into the ATP binding pocket of the unliganded GRP94 N-terminal
domain, a steric clash is observed between the macrocylic amide and the main chain carbonyl
oxygen of Gly196 (Figure 2A). This clash is similar to one predicted for the binding of ATP
to apo GRP9430. To understand how Gdm is accommodated into GRP94, we solved the co-
crystal structure of the GRP94NΔ41-Gdm complex. We used the N-terminal domains for these
studies due to the higher resolution afforded by N-terminal domain complexes compared to
their full length counterparts 31 and because no structures of intact inhibitor-bound hsp90
chaperones have yet been reported. In addition, no differences have been observed between
the dissociation constants for ligands binding to the N-terminal domain of GRP94 compared
to the full length counterpart (R.M.I. & D.T.G., unpublished observations), which suggests
that their mode of interaction is similar. Finally, the structure of intact GRP94 bound to
AMPPNP is consistent with the conformational rearrangements seen in the structure of the
isolated N-terminal domain bound to the same ligand 31. As seen in Figure 2, bound Gdm in
the complex adopts the compact C-shaped cis conformation previously seen in the complexes
with yeast Hsp82 and human Hsp90α 32; 33. As in the Hsp90 complexes, Gdm makes direct
and water mediated hydrogen bonds from its carbamate group to the carboxylate of Asp149,
direct hydrogen bonds to Asp110, Lys114, Gly196, Gly198, and Phe199, and water mediated
contacts to Leu104, Asn107, and Thr254 (Figure 2). The remaining interactions are
hydrophobic contacts between Gdm and residues Met154, Leu163, Val197, and Phe199.
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Earlier co-crystal structures of GRP94 in complex with ATP, ADP, and AMP revealed a
significant rearrangement in GRP94 involving a large displacement of the Helix 1,4,5 mobile
subdomain, compared to the apo enzyme, upon ligand binding34. Surprisingly, despite the fact
that similar regions must move to accomodate ATP or Gdm binding to GRP94, Gdm elicits
only a small rearrangement of the mobile subdomain (Figure 2B). In particular, the structure
of the Gdm-GRP94 complex reveals a ~9 degree rotation at Gly198 in the “Gly hinge” of motif
III of the Bergerat fold 4, compared to the ~95 degree rotation at the same position seen in the
structure of the GRP94NΔ41-ATP complex34. This rotation at Gly198 in the Gdm-GRP94
complex expands the ligand binding pocket by moving Gly196 ~1Å away from the incoming
Gdm, thus avoiding the modeled clash (Figure 2B). As a result of the rotation at Gly198, Helix
5 is slightly displaced and Helix 4 is disordered. This ligand dependent rotation about Gly198
and the displacement of Gly196 are unique to GRP94. These structural rearrangements are also
distinct from the minor structural “tweaks” seen in many Hsp90-ligand complexes because of
their magnitude and because they are driven by a clear necessity to accommodate incoming
Gdm. Adenosine nucleotides and Gdm can be accommodated in the ligand binding pocket of
cytoplasmic Hsp90s without structural re-arrangement, and, unsurprisingly, structural
distortions have not been observed as a result of these or any ligands binding to cytoplasmic
Hsp90s.
Radamide is accommodated differently in GRP94 and yHsp82
To further our understanding of the paralog-specific differences in inhibitor binding we
determined the structures of yeast Hsp82N and GRP94NΔ41 in complex with the radicicol-
geldanamycin chimera Radamide. Radamide contains a resorcinol ring derived from Radicicol
that is linked, via an amide, to the quinone derived from Geldanamycin (Figure 1). Molecules
of this design may be new scaffolds for the development of improved hsp90 targeted
therapeutics.
In both the Hsp90- and GRP94-Radamide complexes, the Radicicol-derived resorcinol ring
makes a direct hydrogen-bonding interaction with the carboxylate of the universally conserved
aspartic acid residue required for ATP binding (Asp79 in yHsp82 and Asp149 in GRP94),
thereby occupying the ligand binding pocket and blocking ATP binding. This orientation is
consistent with the structures of Hsp90 and GRP94 in complex with all of the diaryl resorcinylic
inhibitors 20; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44.
The quinone moiety of Radamide sits at the outside of the ligand binding pocket and is well
ordered in the yHsp82 and GRP94 complexes. As seen in Figure 3A, the quinone of Radamide
contacts yHsp82 through direct hydrogen bonds to Lys44 and Lys98, and additional water
mediated contacts to Lys44, Glu88, Asn91, Asn92, and Lys98. In addition there are also water-
mediated contacts from the amide linkage to Lys98, Gly121, and Phe124.
Surprisingly, while the interactions between the resorcinol ring of Radamide and the binding
pockets of Hsp82 and GRP94 are largely conserved, the quinone moiety adopts two orthogonal
poses when bound to GRP94 that result in novel interactions between the ligand and the protein.
The two quinone orientations have been modeled in the crystal structure determination at 50%
occupancy. As seen in Figure 3B, in the “vertical” orientation, the quinone makes water-
mediated hydrogen bonds to Asn107, Gly196, and Phe199 (Asn37, Gly121, and Phe124 in
yHsp82), while in the “horizontal” configuration the quinone makes direct hydrogen bonds to
Asn162 and Gly196 (Asn92 and Gly121 in yHsp82). Moreover, not only does the quinone of
Radamide make different contacts in the yHsp82 and GRP94 ATP binding sites, it also binds
in an orientation that differs between the two paralogs (Figure 3C, D). For yHsp82, the amide
linkage of Radamide is bent such that the quinone is pointing out towards solvent. In GRP94,
however, the Radamide quinone extends along the back of the ATP binding site and interacts
with a small hydrophobic pocket that is unique to GRP9430. This pocket has been shown to
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accommodate the 5′ extension of the GRP94 specific inhibitor NECA 30, and is blocked in
Hsp90 by Lys168 (Figure 3C). Radamide is thus the first ligand other than NECA and its
derivatives to utilize the 5′ hydrophobic pocket that is unique to GRP94. Additionally,
Radamide is the first example of an inhibitor that has distinct postures in different Hsp90
paralogs.
To test the functional significance of the alternative postures for Radamide in Hsp82 and
GRP94, we measured the binding constant by monitoring the change in the intrinsic tryptophan
fluorescence of the chaperones as a function of Radamide concentration 45. Non-linear least
squares fits to the binding curves yielded Kd values of 0.87 ± 0.14 μM for yHsp82 and 0.52 ±
0.13 μM for GRP94 (Figure 4). It was initially surprising that the binding of Radamide to
GRP94 would be tighter given the lack of a single specific binding mode. The option to bind
in two poses, however, lowers the entropic penalty for the ligand and may account for the
observed tighter binding.
Discussion
Like other members of the GHKL superfamily 4, GRP94 contains an ATP binding site in its
N-terminal domain that is linked to functionally important conformational rearrangements in
the protein 3; 34; 46; 47; 48. In particular, rotation at the Gly hinge in the ATP binding pocket
has been observed in each GHKL family member for which structural data exists 3; 34; 46;
47; 49; 50. By competing with ATP for the nucleotide binding pocket, competitive inhibitors
such as Gdm, Radicicol, and Radamide have been shown to interrupt the function of
Hsp9023; 26; 39; 51 and GRP9416. While the structural details of Gdm binding to Hsp90 have
been previously elucidated 32; 33, we have now described the structure of the GRP94-Gdm
complex.
Gdm binding requires structural rearrangements in GRP94 but not Hsp90
Binding of Gdm to GRP94 requires a rearrangement of the Gly hinge centered at residue
Gly198. The movement of the Gly hinge prevents GRP94 from maintaining the “open”
conformation observed in the un-liganded structure 52 or in co-crystal structures of GRP94
with other inhibitors 30. Moreover, the conformational changes instigated by Gdm binding are
unique among Hsp90 inhibitors; to date the natural ligand ATP and the adenosine nucleotides
are the only other ligands known to produce a rotation at the Gly hinge in any of the GHKL
proteins 34.
The movement at the Gly hinge required for Gdm binding to GRP94 has not been observed
for Gdm binding to Hsp90. Furthermore, Gdm binding to Hsp90 does not lead to any substantial
structural rearrangement 32. This may explain the stronger binding of Gdm 53 and the Gdm
derivative 17-AAG 54 to Hsp90 compared to GRP94.
Given the significant differences between the responses of GRP94 and Hsp90 to Gdm binding
it seems likely that paralog specific inhibitors based on a Gdm scaffold could be designed.
Such inhibitors would be valuable both as tools for probing the biological roles of these
chaperones, and possibly for development of novel therapeutics.
Gdm highlights the role of electrostatics in driving ligand-dependent GRP94 conformational
changes
The observation that Gdm requires an opening of the Gly hinge in GRP94, but does not result
in the “extended open” conformation elicited by ATP, ADP, or AMP binding 34 was initially
perplexing. Docking of either Gdm or ATP into the “open” conformation of apo GRP94 results
in steric clashes with Gly196 that would require some re-arrangement upon actual ligand
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binding. Surprisingly, though, with only modest rotation of the phosphate, docking of AMP
into the pocket of the GRP94-Gdm complex could be accomplished without van der Waals
interpenetration. Since AMP elicits the same “extended open” conformation as ATP, a steric
argument alone cannot explain the different conformations observed in the GRP94-Gdm and
GRP94-ATP complexes.
An analysis of the electrostatics of the binding pocket provides an explanation for the different
magnitude of the protein responses of GRP94 to Gdm and nucleotide binding (Figure 5). The
ATP binding pocket in GRP94 is acidic, and a negative surface potential extends across not
only the region that interacts with the nucleotide base, but also the region that interacts with
the phosphates. Docking of ATP into the binding pocket of apo GRP94 (Figure 5A) would
thus not only result in a steric clash as previously described 30; 34, but also an electrostatic
repulsion caused by the close interaction of the negatively charged phosphates and the acidic
binding pocket. In contrast to ATP, the region of the binding pocket in GRP94 occupied by
Gdm consists of the macrocyclic amide and the quinone (Figure 5B). While these groups are
polar, they are considerably less so than the formally charged phosphates of ATP. As a result,
there would be significantly less electrostatic repulsion upon Gdm binding compared to ATP.
The modeled electrostatic repulsion in addition to the steric clash that arises from ATP binding
to GRP94 may be sufficient to drive the mobile subdomain past an energetic “tipping-point”
that leads to the extended open conformation. Once this required impetus is reached, the
extended open conformation can be stabilized by the interactions described previously 34.
Since Gdm binding to GRP94 leads only to steric rearrangements but not to electrostatic
repulsion, the “tipping-point” is not reached, and GRP94 maintains a conformation close to
that of the apo chaperone.
Interestingly, the electrostatics of the yHsp82 binding pocket are different than those of GRP94
and may help to explain the markedly different responses of the two paralogs to nucleotide
binding. While the region of the pocket that interacts with the nucleotide base is acidic in both
GRP94 and yHsp82, the neighboring phosphate binding regions differ. In yHsp82 this region
is basic and better complements the charge of the nucleotide (Figure 5C), while in GRP94 this
region is acidic and strongly repels the ligand.
Re-design of the Radamide scaffold may lead to paralog-specific inhibitors
The resorcinol ring has been shown to be a useful scaffold for the design of hsp90 inhibitors.
Several diaryl hsp90 inhibitors including the radicicol-geldanamycin chimeras, Radamide and
Radester 23; 26, and the diarylpyrazole class of ligands 20; 35; 37; 38; 40; 41, have taken
advantage of the resorcinol ring to guide binding. Alignment of several resorcinylic diaryl
hsp90 inhibitors shows that the orientation of the second aryl group is highly variable (not
shown).
Although NECA interacts preferentially with GRP94, the use of the NECA scaffold for further
inhibitor development may be limited by the fact that NECA is also a potent agonist of several
cellular Adenosine receptors 55; 56. Previous attempts to design GRP94 specific inhibitors
based on a NECA scaffold have failed to produce ligands with higher affinities than the parent
molecule(R.M.I. and D.T.G., unpublished), although recently another class of purine-based
compounds has shown selective binding to GRP94 (G. Chiosis & D.T.G., in preparation). The
variability in the binding orientation of the second aryl group leads to distinct conformations
of Radamide when bound to yHsp82 or GRP94. Of particular importance, the conformation
of Radamide observed in complex with GRP94 also exploits the GRP94-specific 5′-extension
pocket. Radamide may thus serve as a third useful scaffold for the design of high affinity
GRP94-specific inhibitors.
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All proteins were overexpressed in E. coli strains BL21(DE3) or BL21 Star (DE3). Canine
GRP94(69–337Δ287–327) (GRP94NΔ41), which is 98.5% identical with human GRP94, was
over-expressed as a glutathione S-transferase (GST) fusion, purified as described previously
30; 34; 52, and concentrated to 30 mg/mL in preparation for crystallization. The N-terminal
domain of yeast Hsp90 residues 1–220 (yHsp82N) was over-expressed as an amino-terminal
hexa-Histidine tagged protein and purified by Ni-NTA affinity chromatography followed by
dialysis, ion exchange chromatography on Q-sepharose (pH 8.0), and gel filtration
chromatography on an S200. The purified protein was concentrated to 33 mg/mL in preparation
for crystallization.
Near full-length His-tagged GRP94 28–754(Δ287–327) (GRP94-NMC) was expressed and
purified essentially as described 31. Full length yeast His-tagged Hsp82 (residues 1-709) in
pDEST17 (Invitrogen) was overexpressed in E. coli BL21 Star (DE3) and purified by Ni-NTA
affinity chromatography followed by dialysis, ion exchange chromatography on Q-sepharose
(pH 8.0), and gel filtration chromatography on an S200.
Radamide was synthesized as previously reported 23; 26.
Crystallization of Inhibitor bound GRP94NΔ41
Crystals of GRP94NΔ41 in complex with Gdm were grown by hanging-drop vapor diffusion
at 18°C. Prior to crystallization, the ligand was added to the concentrated protein in 10mM
Tris, pH 7.6, 100mM NaCl, 1mM DTT to a final concentration of 3–10mM. The drops were
formed by adding a 1:1 ratio of protein to reservoir (34% w/v PEG400, 60mM MgCl2, 100mM
Tris, pH 7.6). Rod shaped crystals with typical dimensions of 400 × 200 × 200 μm appeared
after 2–3 days.
Crystals of GRP94Δ41 in complex with Radamide were grown by hanging-drop vapor
diffusion at 18°C. The crystallization drops contained 5–10mM ligand (a 5–10 molar excess)
and a 1:1 ratio of protein to reservoir (25–30% w/v PEG MME 550, 10mM MgCl2, 100mM
Tris, pH 8.0). Diffraction quality crystals appeared after 3–4 days. Typical crystals were rods
with edge lengths of 400 × 100× 200 μm.
In each case crystals were harvested with nylon loops and cryo-protected by stepwise capillary
transfers of the crystals to solutions that gradually increased the concentration of PEG 400 to
44–46%. If crystals were grown in PEG MME 550 the first capillary transfer was from the
mother liquor to a solution that replaced the PEG MME 550 with PEG 400. Following the final
equilibration the crystals were flash cooled in liquid nitrogen.
Crystallization of Inhibitor bound yHsp82N
Crystals of yHsp82N in complex with Radamide were grown at 18°C by microbatch under
mineral oil. The microbatch drops contained ~10mM Radamide (a 10-fold molar excess) and
a 4:1 ratio of protein (33mg/mL Hsp90 in 10mM Tris pH 7.6, 100mM NaCl 1mM DTT) to
precipitant (8–9% w/v PEG MME 550, 25% glycerol, 90mM CaCl2, and 30mM Sodium
Acetate or Sodium Succinate, pH 5.0). Tetragonal bi-pyramid crystals with a typical edge
length of 200 μm appeared after 2–3 days. Crystals were harvested with nylon loops and cryo-
protected by equilibration in 50mM Tris pH 7.4, 25% glycerol, 90mM CaCl2, and 13.5% PEG
MME 550. Directly following cryo-protection, crystals were flash cooled in liquid nitrogen.
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Data Collection, Structure Determination and Refinement
X-ray diffraction data for the GRP94NΔ41-Gdm co-crystals was collected on an R-AxisIV
detector using X-rays from a rotating anode generator. Data for crystals of yHsp82N or
GRP94NΔ41 with bound Radamide were collected on a MAR-225 CCD detector at APS
beamline 22-BM. Data were reduced and scaled using XDS 57. Initial phases for the co-crystals
were obtained by molecular replacement (MR). The search model for GRP94 constructs was
the core region (residues 69–166 and 200–337) of apo GRP94NΔ41 (PDBID 1YT1) 52, and
the search model for yHsp82 constructs was PDBID 1AH658; 59. The molecular replacement
and following intermediate models were manually rebuilt in O or Coot, and refined in CNS,
CCP4, or PHENIX 60; 61; 62; 63; 64. Ligand and solvent molecule positions were identified
by overlapping peaks of difference density and simulated annealing omit density. Parameter
and topology files for Gdm were obtained from HIC-Up, while parameter and topology files
for Radamide were generated using the Dundee PRODRG server 65.
In later rounds of refinement, ligand dihedral constraints were relaxed, alternate sidechain
conformations were added, and restrained individual B-factors were used. Structure validation
was performed using KiNG and MolProbity 66; 67; 68; 69; 70. Data collection and refinement
statistics are shown in Table I. Molecular graphics were created using Pymol (DeLano
Scientific, San Carlos, CA).
Tryptophan Fluorescence Binding Assays
500 μL of GRP94-NMC or full length yHsp82 at a concentration of 0.1 μM in 1× buffer (40
mM Hepes, pH 7.4, 150 mM KCl, 5 mM MgCl2) was titrated with sequential 5 μL additions
of Radamide solutions of increasing concentration (0.1 μM, 1 μM, 10 μM, 75 μM, 100 μM,
150 μM, 200 μM, 300 μM, 400 μM, 600 μM, 800 μM, 1200 μM, 1600 μM, 3200 μM). Ligand
dilutions were made in 1× buffer from a 3200 μM stock in 50% DMSO such that the carryover
DMSO in the titration did not exceed 2.5% (v/v). Fluorescence at 340 nm was monitored in a
Jovin-Youbain fluorometer using an excitation wavelength of 275 nm, with 3 nm slits.
Correction for the internal absorbance of the Radamide was made to the fluorescence data by
applying the negative of the exponential derived from the fit of a similar Radamide titration of
a solution of 5 μM L-Trp. Fluorescence data was also corrected for dilution. Corrected binding
curves were analyzed using the one-site total binding model in Prism. Errors were estimated
from the standard deviation of three replicate titrations.
Electrostatic potential maps for GRP94 and yHsp82
Surface potential maps were generated for the N-terminal domains of both GRP94 and yHsp82.
In preparation for charge calculations, the structures were stripped of waters and heterogens
and the atoms missing from truncated sidechains were added. The modified structures were
then used to calculate the electrostatic potentials using Adaptive Poisson-Boltzman Solver
APBS 71, and Gemstone (http://gemstone.mozdev.org).
Coordinates
Structure factors and coordinates have been deposited in the PDB 72. The corresponding PDB
codes for these structures are: 2FXS for yHsp82N-Radamide, 2GFD for GRP94NΔ41-
Radamide, and 2EXL for GRP94NΔ41-GDM.
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Ansamycin antibiotics Geldanamycin (Gdm) and Radicicol (Rdc), and the chimeric Hsp90
inhibitor Radamide. The quinone in common between Radamide and Gdm is colored in red.
The resorcinol ring in common between Radamide and Rdc is colored in dark blue. The
positions around the resorcinol ring are numbered.
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(A) Modeling of Gdm into the nucleotide binding pocket of the un-liganded structure of
GRP94NΔ41(slate) based on the position of Gdm in the GRP94NΔ41-Gdm complex results
in a steric clash with Gly196. (B) Authentic structure of the GRP94NΔ41-Gdm complex (lime).
Van der Waals spheres (blue dots) for the nitrogen of the macrocyclic amide no longer
interpenetrate the carbonyl of Gly196 (red and lime dots). Binding of Gdm is accompanied by
a rearrangement of the Gly hinge and a small displacement of the preceding Helix5. (C)
Stereodiagram of the binding pocket interactions for Gdm in the GRP94NΔ41-Gdm complex.
Water molecules are shown as red spheres and hydrogen bonds as dashed lines.
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Stereodiagram of the interactions between Radamide and (A) yHsp82 or (B) GRP94. Red
spheres represent water molecules, and dashed yellow lines represent hydrogen bonds. In panel
(B) the “vertical” orientation of the quinone is solid, and the “horizontal” orientation is semi-
transparent. In both (A) and (B) the model density (2Fo-Fc model map contoured at 1.0σ carved
at 1.8Å around selected atoms, blue) is displayed for the bound Radamide. The surface
representations of Radamide in the ATP binding site of (C) yHsp82 and (D) GRP94 are shown
to compare the orientation and trajectory of bound Radamide in the co-crystal complexes. In
panel (C) Radamide makes an oblique angle with the back of the ATP binding site and extends
slightly into solvent. Radamide bound to GRP94 (D) utilizes the small hydrophobic 5′-
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extension pocket. The two alternate conformations of Radamide (D) are colored with white
carbons for the horizontal orientation of the quinone and grey carbons for the vertical
orientation of the quinone.
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Tryptophan fluorescence titration for binding of Radamide to full-length yHsp82 and GRP94-
NMC. The different poses for Radamide in the yHsp82 and GRP94 binding pockets result in
disparate binding affinities. Radamide bound to GRP94 exhibits two alternate conformations
and has a Kd of 0.52 ± 13 μM compared to 0.87 ± 14 μM for yHsp82.
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Modeling of ADP (A), and Gdm (B) into the apo conformations of GRP94NΔ41 and modeling
of ADP into the apo conformation of yHsp82N (C). Electrostatic surface potentials were
generated using APBS 71, and Gemstone (http://gemstone.mozdev.org). The phosphates of
ADP interact with an acidic region of the GRP94NΔ41 ATP binding pocket (A) leading to a
modeled electrostatic repulsion. The region of Gdm (B) that interacts with this portion of the
GRP94 binding pocket is not charged and therefore no electrostatic repulsion would result from
Gdm binding. Yeast Hsp82 unlike GRP94 has a basic patch in its ATP binding pocket (C).
This basic region interacts with the negatively charged phosphates, and better compliments
ATP than GRP94.
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Table I
Summary of Data Collection and Refinement Statistics
Diffraction Data GRP94NΔ41 + GDM GRP94NΔ41 + Radamide yHsp82N + Radamide
Diffraction Data Statistics
PDB code 2EXL 2GFD 2FXS
Source RaxisII APS 22-BM APS 22-BM
Space Group P212121 P212121 P4322
 a, b, c (Å) 65.82, 84.36, 95.63 65.49, 84.57, 95.58 75.20, 75.20, 110.85
Wavelength (Å) 1.5418 0.99997 0.99997
Resolution (Å)a 50–2.30 50–2.15 50–2.0
 (Last Shell) (Å) 2.4–2.3 2.25–2.15 2.05–2.00
Unique Reflections 22646 29502 21635
Completeness (Last Shell) (%) 93.2 (46.5) 99.8 (100) 99.9 (99.9)
Average I/σI (Last Shell) 12.1 (3.5) 15.8 (5.6) 29.8 (5.7)
Redundancy 3.9 7.2 14.0
Rsymb (Last Shell) (%) 9.9 (28.8) 8.4 (38.6) 6.9 (46.3)
Refinement Statistics
Refinement Package CNS 1.1 CNS 1.1 CNS 1.1
Resolution range (Å) 50–2.35 50–2.3 50–2.0
Reflections 22516 24181 21617
Non-solvent atomsc 3249 3352 1686
Solvent and hetero- atomsc 430 408 321
Molecules in Asymmetric Unit 2 2 1
Rms deviation from ideality
 Bond lengths (Å) .00621 0.00596 .00562
 Bond angles (°) 1.310 1.237 1.340
Rd value (%) 22.1 21.1 19.6
Rd free (%) 27.6 25.4 22.6
a
Resolution limit was defined as the highest resolution shell where the average I/σI was >2.
b
Rmerge = ΣhklΣi|Ii(hkl) - <I(hkl)>|/ΣhklΣII(hkl).
c
Alternate atoms are counted once.
d
R = Σ|Fo - Fc|/ΣFo. 10% of reflections were used to calculate Rfree.
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